Cancer Management and Research
Volume 14, 2022 - Issue
Open access
96
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH
Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors
Priyanka Gaitonde1 AstraZeneca, Health Economics & Payer Evidence, Gaithersburg, MD, USACorrespondence[email protected]
View further author information
, View further author information
Viktor Chirikov2 OPEN Health Evidence & Access, Bethesda, MD, USAView further author information
, Sneha Kelkar2 OPEN Health Evidence & Access, Bethesda, MD, USAView further author information
& Bengt Liljas1 AstraZeneca, Health Economics & Payer Evidence, Gaithersburg, MD, USA
https://orcid.org/0000-0002-9411-7087View further author information
Pages 3421-3435
|
Received 28 Jul 2022, Accepted 27 Oct 2022, Published online: 27 Nov 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.